Effect of Metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 4, 2013, Pages 806-813

  Esfahanian, Fatemeh ^a   Zamani, Mohammad Mahdi ^a,b   Heshmat, Ramin ^b   Moini Nia, Fatemeh ^a,c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d University of Medical Sciences   (Iran)

Author keywords

C reactive protein; Hypocaloric diet; Insulin resistance; Metformin; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; METFORMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW CALORY DIET; OBESITY; OVARY POLYCYSTIC DISEASE; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; C-REACTIVE PROTEIN; DIET, REDUCING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; OBESITY; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS; YOUNG ADULT;

EID: 84880019771     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.02051.x     Document Type: Article

References (43)

1. Ehrmann D. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
3. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L. The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 2-5.
4. Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril 2006; 86: S20-SS1.
5. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-369.
6. Ridker P. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
7. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O. Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-2165.
8. Christian R, Dumesic D, Behrenbeck T, Oberg A, Sheedy P, Fitzpatrick L. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 2562-2568.
9. Teede H, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30: 45-53.
10. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol 2010; 162: 1093-1099.
11. Birdsall M, Farquhar C, White H. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126: 32-35.
12. Tsilchorozidou T, Mohamed-Ali V, Conway G. Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short-and long-term metformin therapy. Horm Res Paediatr 2009; 71: 148-154.
13. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139-146.
14. Lord J, Flight I, Norman R. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003; 327: 951-955.
15. Diamanti-Kandarakis E, Christakou C, Kandaraki E, Economou F. Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol 2010; 162: 193-212.
16. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen J. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4649-4654.
17. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006; 21: 1426-1431.
18. Nicholson F, Rolland C, Broom J, Love J. Effectiveness of long-term (twelve months) nonsurgical weight loss interventions for obese women with polycystic ovary syndrome: A systematic review. Int J Wom Health 2010; 2: 393-399.
19. Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-2712.
20. Crosignani P, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: Parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18: 1928-1932.
21. Fauser B, Tarlatzis B, Chang J, Azziz R, Legro R, Dewailly D. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
22. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
24. Wild R, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale H, Futterweit W. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95: 2038-2049.
25. Yildiz B, Knochenhauer E, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93: 162-168.
26. Creanga A, Bradley H, McCormick C, Witkop C. Use of metformin in polycystic ovary syndrome: A meta-analysis. Obstet Gynaecol 2008; 111: 959-968.
27. Tang T, Lord J, Norman R, Yasmin E, Balen A. Insulinsensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2010; (1): CD003053. pub4.
28. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93: 82-90.
29. Kelly C, Lyall H, Petrie J, Gould G, Connell J, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-2455.
30. Puder J, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: Relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005; 90: 6014-6021.
31. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen J. Endocrine and metabolic effects of metformin versus ethinyl stradiol-cyproterone acetate in obese women with polycystic ovary syndrome: A randomized study. J Clin Endocrinol Metab 2000; 85: 3161-3168.
32. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-2774.
33. Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Hum Reprod 2006; 21: 3108-3115.
34. Ciampelli M, Leoni F, Apa R, Lanzone A. A pilot study of the long term effects of acipimox in polycystic ovarian syndrome. Hum Reprod 2002; 17: 647-653.
35. Vause T, Cheung A, Sierra S, Claman P, Graham J, Guillemin JA. Ovulation induction in polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 111: 95-100.
36. Cleeman J, Grundy S, Becker D, Clark L. Expert panel on Detection, Evaluation and Treatment of High blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP)Adult Treatment Panel (ATP III). JAMA 2001; 285: 2486-2497.
37. Kaku K, Tajima N, Kawamori K. Melbin Observation Research (MORE) study of metformin therapy in patients with type 2 diabetes mellitus. J Jpn Diab Soc 2006; 49: 325-331.
38. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977; 2: 1576-1578.
39. Yajima K, Shimada A, Hirose H, Kasuga A, Saruta T. 'Low dose' metformin improves hyperglycemia better than acarbose in type 2 diabetics. Rev Diabet Stud 2004; 1: 89-94.
40. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: Results from a randomized crossover trial. Diabetes Obes Metab 2007; 9: 394-407.
41. Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 2009; 339: b4324.
42. Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, Togane M. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metab 2010; 7: 83.
43. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER. The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med 2006; 23: 128-133.